<DOC>
	<DOCNO>NCT01109316</DOCNO>
	<brief_summary>This 6-sequence , 3-period ( 8 week ) , 3-arm , 24-week crossover study . The purpose study provide information use insulin lispro insulin pump ( Continuous Subcutaneous Insulin Infusion [ CSII ] ) compare insulin aspart 6 day pump reservoir in-use . The study also compare in-use characteristic insulin lispro infuse 6 day insulin lispro infused 2 day .</brief_summary>
	<brief_title>Insulin Lispro 6 Days Versus Insulin Aspart 6 Days Pump Use</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Diagnosed type 1 diabetes ( World Health Organization criterion ) least 24 month . Treated continuous subcutaneous insulin infusion therapy previous 6 month . Mean total daily insulin dose 3 day prior screen equal le 46 units/day use 300unit reservoir less equal 26 units/day use 180 unit reservoir . Baseline body mass index ( BMI ) less equal 35.0 kg/m^2 . Baseline glycosylated hemoglobin ( HbA1c ) 5 % 9 % . Impaired renal function ( serum creatinine great equal 2.0 milligram per deciliter [ mg/dL ] ) . Legal blindness . Have episode hypoglycemic coma , seizure , disorientation 12 month prior screen . Have hypoglycemia unawareness ( routinely asymptomatic blood glucose ( BG ) less 45 mg/dL ) 12 month prior screen . Have emergency room visit hospitalization due poor glucose control 12 month prior screen . Have pumprelated infusion site abscess 12 month prior screen . Have multiple , clinically significant occlusion judge investigator . Have infection staphylococcus aureus past 5 year . Have one follow concomitant disease : presence clinically significant hematologic , oncologic , renal , cardiac , hepatic , gastrointestinal disease , serious disease consider investigator exclusionary . Patients malignancy basal cell squamous cell skin cancer yet treat , currently treat , diagnose less 5 year ago . Have blood transfusion severe blood loss within 3 month prior screen , know hemoglobinopathy , hemolytic anemia sickle cell anemia , traits hemoglobin abnormality know interfere HbA1c methodology . Are receive chronic ( lasting longer 14 consecutive day ) systemic glucocorticoid therapy ( exclude topical , intraarticular , intraocular inhale prescription ) , receive therapy within 4 week immediately precede screen . Have irregular sleep/wake cycle ( example , patient sleep day work night ) , investigator 's opinion . Have know hypersensitivity allergy study insulins excipients . Are breastfeed pregnant , intend become pregnant course study , sexually active woman childbearing potential actively practice birth control method determine investigator medically acceptable . Are currently enrol , discontinue within last 30 day , clinical trial involve offlabel use investigational drug device ( study drug/device use study ) , concurrently enrol type medical research judge scientifically medically compatible study . Have previously complete withdrawn study sign informed consent document ( ICD ) . Are unwilling unable comply use data collection device directly record data patient .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>